Raymond James lowered the firm’s price target on UnitedHealth (UNH) to $540 from $635 and keeps a Strong Buy rating on the shares. The company reported a miss at Medicare Advantage risk in Optum Health as the company cited elevated utilization levels and lower than anticipated risk scores from new members from non-UnitedHealth MA plans, and the company lowered its 2025 guidance for adjusted EPS, the analyst tells investors in a research note. The firm believes most of UnitedHealth’s issues are company-specific.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $520 from $609 at TD Cowen
- UnitedHealth price target lowered to $600 from $640 at Oppenheimer
- UnitedHealth price target lowered to $560 from $700 at BofA
- UnitedHealth downgraded to Hold from Buy at Argus
- UnitedHealth’s Resilience and Recovery: Analyst Recommends ‘Buy’ Amid Challenges and Optimistic Outlook